Erdafitinib With EV Following Platinum, PD-1/L1 Inhibitors for mUC with FGFR3/2 Alterations

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Rohit K. Jain, MB, BS, MD, of Weill Cornell Medicine, spoke to his study, ETCTN 10483, and the rationale for combining erdafitinib with EV in metastatic urothelial carcinoma patients with FGFR3/2 genetic alterations.

He highlighted the safety results, dose-escalation phase of the trial, and accumulated data to date on responses and overall survival.